Kenalog Intra-Articular / Intramuscular (Triamcinolone Acetonide)

Triamcinolone acetonide binds to intracellular glucocorticoid receptors, altering gene transcription to suppress pro‑inflammatory cytokines and chemokines while enhancing anti‑inflammatory proteins, which collectively reduces inflammation and immune cell activity at the injection site.

The specific dose and volume are determined by the prescribing clinician based on the joint involved, severity of inflammation, and patient factors. Dosing is individualized and should follow the prescriber’s instructions.

Safety data are limited; the product should be used during pregnancy or lactation only if the potential benefit justifies the potential risk. Clinicians should discuss risks with the patient and consider alternative therapies when appropriate.

Enquiries are submitted via the product page at gnhindia.com, where you specify the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, confirming trade or institutional credentials before providing pricing, availability, shipping details (including any cold‑chain requirements) and import documentation.

Kenalog (triamcinolone acetonide) offers a medium‑duration anti‑inflammatory effect and is often chosen for its potency and solubility profile. Compared with methylprednisolone or betamethasone, it may provide a slightly longer duration of action, but the choice depends on clinician preference, patient response and specific joint considerations.

The product should be stored at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the vial in its original packaging until use to maintain stability.

The medication is supplied as a sterile injectable suspension and is administered by a qualified healthcare professional directly into the affected joint (intra‑articular) or muscle (intramuscular) using aseptic technique.

Serious risks include adrenal suppression, severe infections, osteonecrosis, and rare allergic reactions such as anaphylaxis. Patients should be monitored for signs of systemic corticosteroid effects and any unexpected symptoms after injection.

Patients with uncontrolled systemic infections, known hypersensitivity to triamcinolone or any formulation component, and those for whom corticosteroids are contraindicated (e.g., certain viral infections, uncontrolled diabetes) should avoid this product unless a risk‑benefit assessment justifies use.